Isconova’s rights issue fully subscribed
The new share issue in Isconova AB (publ) (”Isconova” or the ”Company”) with preferential rights for the Company’s shareholders, for which the subscription period ended on 29 October 2012 (the ”Rights Issue”), has been fully subscribed. The Rights Issue will provide Isconova with approximately SEK 50 million before costs related to the Rights Issue. Following the Rights Issue, the number of shares in Isconova will increase by 8 316 904 shares from 4 158 452 shares to a total of 12 475 356 shares and the share capital will increase by SEK 8 316 904 from SEK 4 158 452 to SEK 12 475 356.
5 399 801 shares, corresponding to approximately 64.9 per cent of the Rights Issue, have been subscribed for with subscription rights and 41 371 shares, corresponding to approximately 0.5 per cent of the Rights Issue, have been subscribed for without subscription rights. Persons that have subscribed for shares without subscription rights have been allocated shares in accordance with the principles outlined in the prospectus that has been compiled in relation to the Rights Issue and was made public on 2 October 2012. The remainder, 2 875 732 shares, corresponding to 34.6 per cent of the Rights Issue, has been subscribed for by the investors who committed to underwrite the Rights Issue.
Pareto Öhman AB is financial advisor and Advokatfirman Lindahl KB is legal advisor to Isconova in connection with the Rights Issue.
For further information, please contact
Sven Andréasson, CEO, +46 701 60 60 60
This press release contains information that Isconova is required to announce pursuant to the Swedish Securities Market Act (2007:528). The information was submitted for publication (approximately) 08.00 AM on 2 November 2012.
Isconova AB is a leading international vaccine adjuvant company. Isconova has deep knowledge of vaccine systems, and the company develops vaccines together with partners in the human and veterinary markets. The first vaccine using Isconova’s nano-particle Matrix technology, Equilis®Prequenza, was launched on the veterinary market in 2006. In the human market a number of vaccines are under development with Isconova’s third generation nano-particle, Matrix M™. Isconova’s partners include J&J/Crucell, Pfizer, Merck & Co., The Jenner Institute, Genocea and Evolva. The Company is headquartered in Uppsala, Sweden. Isconova AB was listed on NASDAQ OMX First North (ticker: ISCO) in November 2010. www.isconova.com.
This press release is not an offer or solicitation to acquire shares in Isconova.
This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended. Isconova does not intend to register any portion of the offering of the securities in the United States or to conduct a public offering of the securities in the United States. The information in this press release may not be announced, published or distributed, directly or indirectly, to the United States, Canada, Australia, Singapore, South Africa, Switzerland, Japan or Hong Kong or in any other jurisdiction where the announcement, publication or distribution of the information would not comply with applicable laws and regulations.
 The costs related to the Rights Issue are estimated to amount to approximately SEK 5 million.